Literature DB >> 12195825

Effect of hr-IL2 treatment on intestinal P-glycoprotein expression and activity in Caco-2 cells.

Anne-Marie Belliard1, Sylviane Tardivel, Robert Farinotti, Bernard Lacour, Christine Leroy.   

Abstract

Caco-2 cells were used to investigate the effect of human recombinant interleukin-2 (IL2) on intestinal P-glycoprotein (P-gp) transporter activity in-vitro. More specifically the efflux function of P-gp was studied by measuring the transepithelial transport of rhodamine-123, a fluorescent substrate of P-gp. Its transport was completely inhibited by two specific P-gp inhibitors, ciclosporin A and GG918, in our experiments. Conversely, these two specific P-gp inhibitors inhibited only 50% of transepithelial transport when [3H]vincristine was used as substrate. After Caco-2 cells were treated with 100 IU mL-1 (6.1 ng mL-1) IL2 for 24 h, a significant diminution (21%) of P-gp transporter function was observed with rhodamine-123 substrate. This effect was also confirmed after 48 and 72 h of exposure to IL2. However, for higher concentrations of IL2 (1000 and 5000 IU mL-1), diminution of P-gp function only occurred after a longer treatment period (48 h and more). The inhibitory effect of IL2 on P-gp activity was found to be independent of tight junction function as demonstrated by constant transepithelial electrical resistance (TEER) measurements for all experimental conditions encountered in this study (time and concentration of IL2 exposure). Furthermore, the MDR1 mRNA level was found to be strongly repressed in Caco-2 cells exposed with 1000 IU mL-1 IL2 for 72 h while the amount of MRP1 mRNA remained unchanged. In conclusion, acute incubation of Caco-2 cells with IL2 induced a decrease of P-gp transporter expression and activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12195825     DOI: 10.1211/002235702320266262

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  5 in total

Review 1.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

Review 2.  Mouse models of neurological disorders: a view from the blood-brain barrier.

Authors:  William A Banks
Journal:  Biochim Biophys Acta       Date:  2009-10-29

3.  Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation.

Authors:  Laurence Bousquet; Alain Pruvost; Anne-Cécile Guyot; Robert Farinotti; Aloïse Mabondzo
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

4.  Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.

Authors:  Raymond Evers; Micheline Piquette-Miller; Joseph W Polli; Frans G M Russel; Jason A Sprowl; Kimio Tohyama; Joseph A Ware; Saskia N de Wildt; Wen Xie; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2018-07-12       Impact factor: 6.875

5.  Immunological response as a source to variability in drug metabolism and transport.

Authors:  Hege Christensen; Monica Hermann
Journal:  Front Pharmacol       Date:  2012-02-10       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.